Can SARS-CoV-2’s impairment of endothelium cause vascular disease?

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen that causes the coronavirus disease (COVID-19), contains the spike protein that binds with the human angiotensin-converting enzyme 2 (ACE2) receptor to enter and infect host cells.

Researchers in the U.S. and China have revealed that SARS-CoV-2's spike protein does not only latch and bind to healthy cells for infection, but also plays a key role in the disease process.

The study, published in the journal Circulation Research, suggests that COVID-19 is not only a respiratory disease but also a vascular disease. It highlights how the virus attacks the vascular system, causing endothelial impairment.

Study: The novel coronavirus’ spike protein plays additional key role in illness. Image Credit: Wetzkaz Graphics / Shutterstock
Study: The novel coronavirus’ spike protein plays additional key role in illness. Image Credit: Wetzkaz Graphics / Shutterstock

Vascular disease

The spike protein plays a pivotal role in the receptor recognition and cell membrane fusion process. It is composed of two subunits – S1 and S2. The S1 subunit contains the receptor-binding domain (RBD) that binds to the host receptor ACE2. The subunit S2 mediates viral cell membrane fusion by generating a six-helical bundle.

The vascular endothelium can be infected by SARS-CoV-2, triggering mitochondrial reactive oxygen species production and glycolytic shift.

In the current study, the team showed that S protein alone could damage vascular endothelial cells (ECs) by downregulating ACE2 and limiting mitochondrial function. Endothelial cells line the blood vessels in the body, which are crucial for blood circulation.

The team used a "pseudovirus" that was adorned with SARS-CoV-2 spike proteins to arrive at the study findings. They administered the pseudovirus expressing S protein (pseu-spike) to Syrian hamsters directly into the trachea. The animals that received the pseudovirus exhibited lung damage.

Further, the study revealed that exposure to the pseudovirus resulted in damage to the animals' arteries, showing that the Spike protein alone causes disease. The team also found that the endothelial cells lining the pulmonary artery walls were inflamed in tissue samples.

Representative images of vascular endothelial control cells (left) and cells treated with the SARS-CoV-2 Spike protein (right) show that the spike protein causes increased mitochondrial fragmentation in vascular cells.
Representative images of vascular endothelial control cells (left) and cells treated with the SARS-CoV-2 Spike protein (right) show that the spike protein causes increased mitochondrial fragmentation in vascular cells.

The team performed another experiment in the laboratory by exposing healthy endothelial cells to the spike protein. The results showed that the spike protein damaged the cells by binding with ACE2. The attachments altered ACE2's molecular signaling to the mitochondria, causing mitochondrial fragmentation.

When the cells were exposed to the spike protein, mitochondrial fragmentation resulted in altered mitochondrial dynamics.

If you remove the replicating capabilities of the virus, it still has a major damaging effect on the vascular cells, simply by virtue of its ability to bind to this ACE2 receptor, the S protein receptor, now famous thanks to COVID," Assistant Research Professor Uri Manor, a study co-author, said.

"Further studies with mutant spike proteins will also provide new insight towards the infectivity and severity of mutant SARS CoV-2 viruses," they added.

Further studies are needed to assess how the disrupted ACE2 protein damages mitochondria and causes structural changes.

COVID-19 situation

To date, more than 152.97 million people have been infected with SARS-CoV-2. Of these, 3.20 million have died. People are at a high risk of developing severe COVID-19, including older adults, those with comorbidities, and those who have weakened immune systems.

Source:
Journal reference:
Angela Betsaida B. Laguipo

Written by

Angela Betsaida B. Laguipo

Angela is a nurse by profession and a writer by heart. She graduated with honors (Cum Laude) for her Bachelor of Nursing degree at the University of Baguio, Philippines. She is currently completing her Master's Degree where she specialized in Maternal and Child Nursing and worked as a clinical instructor and educator in the School of Nursing at the University of Baguio.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Laguipo, Angela. (2021, May 04). Can SARS-CoV-2’s impairment of endothelium cause vascular disease?. News-Medical. Retrieved on November 22, 2024 from https://www.news-medical.net/news/20210504/Can-SARS-CoV-2e28099s-impairment-of-endothelium-cause-vascular-disease.aspx.

  • MLA

    Laguipo, Angela. "Can SARS-CoV-2’s impairment of endothelium cause vascular disease?". News-Medical. 22 November 2024. <https://www.news-medical.net/news/20210504/Can-SARS-CoV-2e28099s-impairment-of-endothelium-cause-vascular-disease.aspx>.

  • Chicago

    Laguipo, Angela. "Can SARS-CoV-2’s impairment of endothelium cause vascular disease?". News-Medical. https://www.news-medical.net/news/20210504/Can-SARS-CoV-2e28099s-impairment-of-endothelium-cause-vascular-disease.aspx. (accessed November 22, 2024).

  • Harvard

    Laguipo, Angela. 2021. Can SARS-CoV-2’s impairment of endothelium cause vascular disease?. News-Medical, viewed 22 November 2024, https://www.news-medical.net/news/20210504/Can-SARS-CoV-2e28099s-impairment-of-endothelium-cause-vascular-disease.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Inequities in COVID-19 vaccination coverage for older adults highlighted in global study